Could some cirrhosis patients avoid screening endoscopy? Baveno VI uses FibroScan and platelet count to identify those at low ...
Patients with cirrhosis and obesity who undergo bariatric surgery see survival benefits over 10 years that make the surgery cost-effective compared with people who only receive a lifestyle ...
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately ...
Nonalcoholic fatty liver disease (NAFLD), now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe form, nonalcoholic steatohepatitis (NASH), renamed ...
RTX001, an engineered Regenerative Macrophage Therapy designed to address inflammation and fibrosisEMERALD is evaluating ...
Please provide your email address to receive an email when new articles are posted on . Over the 6-year study period, 23.5% of patients with cirrhosis had a DEXA scan ordered and 12.5% completed the ...
2d
Can-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant
Detailed price information for Can-Fite Biopharma Ltd ADR (CANF-A) from The Globe and Mail including charting and trades.
The benefits of many elective nonhepatic surgeries outweigh the risks for select patients with compensated cirrhosis, but those at high risk for poor surgical outcomes should continue to seek ...
Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results